Strategic Partnerships HAYA Therapeutics has active collaborations and significant funding from notable investors and big pharma interest, including Eli Lilly partnerships and a $65M Series A led by Sofinnova Partners and Earlybird. This signals a strong validation path for co-development, licensing, or strategic alliances in RNA-guided therapies and obesity programs.

Pipeline Targeting The company focuses on RNA-guided therapeutics targeting regulatory genomes and lncRNAs with lead candidate HTX-001 aimed at Wisper in heart failure, plus a broader pipeline across lungs and solid tumor microenvironments. This presents opportunities to position solutions for RNA biology tooling, regulatory RNA discovery services, and novel antisense or delivery platforms.

Geographic Footprint Operations span Lausanne Biopôle with Lilly Gateway Labs in San Diego, indicating access to European and North American ecosystems. A BD approach can emphasize cross-border collaborations, translational research milestones, and access to diverse clinical trial sites.

Funding Vigor A substantial funding runway of about one billion dollars in total funding underscores strong financial health and potential for long-duration partnerships, enabling multi-year co-development deals, milestone-driven licensing, and joint venture opportunities in rare and chronic disease programs.

Market Readiness Recognition of leadership and innovation in the RNA therapeutics space, including awards and media coverage, coupled with a growing obesity-focused collaboration narrative, suggests a receptive market and clear case for early-access programs, platform licensing, and contract research or development services aligned to regulatory-genome targeting.